Publications of Roman K. Thomas
All genres
Journal Article (72)
2011
Journal Article
1 (1), pp. 78 - 89 (2011)
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery
Journal Article
17 (23), pp. 7394 - 7401 (2011)
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clinical Cancer Research
Journal Article
71 (14), pp. 4920 - 4931 (2011)
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Research
Journal Article
17 (11), pp. 1504 - 1508 (2011)
A crucial requirement for Hedgehog signaling in small cell lung cancer. Nature Medicine
Journal Article
6 (5), p. e19601 - e19601 (2011)
Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS ONE
Journal Article
17 (10), pp. 3360 - 3367 (2011)
Blood-based gene expression signatures in non-small cell lung cancer. Clinical Cancer Research
Journal Article
29 (13), pp. 1701 - 1708 (2011)
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [18F] fluorodeoxyglucose and [ 18F] fluorothymidine positron emission tomography. Journal of Clinical Oncology 2010
Journal Article
5 (3), pp. 407 - 409 (2010)
Osteoblastic response in patients with non-small cell lung cancer with activating EGFR mutations and bone metastases during treatment with EGFR kinase inhibitors. Journal of Thoracic Oncology
Journal Article
143 (2), pp. 201 - 211 (2010)
Cytohesins are cytoplasmic ErbB receptor activators. Cell
Journal Article
38 (20), pp. 6985 - 6996 (2010)
Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Nucleic Acids Research
Journal Article
53 (7), pp. 2892 - 2901 (2010)
Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor. Journal of Medicinal Chemistry
Journal Article
5 (1), p. e8919 - e8919 (2010)
Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling. PLoS ONE
Journal Article
17 (10), pp. 298 - 310 (2010)
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell
Journal Article
70 (3), pp. 868 - 874 (2010)
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Research
Journal Article
2 (62), p. 62ra93 - 62ra93 (2010)
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine
Journal Article
28 (29), pp. 4417 - 4424 (2010)
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. Journal of Clinical Oncology 2009
Journal Article
8 (22), pp. 3652 - 3656 (2009)
Systematically linking drug susceptibility to cancer genome aberrations. Cell Cycle
Journal Article
462 (7269), pp. 108 - 112 (2009)
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature
Journal Article
8 (21), pp. 2042 - 2050 (2009)
Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biology and Therapy
Journal Article
106, pp. 18351 - 18356 (2009)
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America